REVIEW ARTICLE

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence

David F. Archer, MD,1 Bruce R. Carr, MD,2 JoAnn V. Pinkerton, MD,3 Hugh S. Taylor, MD,4 and Ginger D. Constantine, MD5

Abstract

Objective: Treatment of menopausal symptoms by compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, has been researched as an alternative to the use of estrogen therapy. These structurally diverse molecules elicit tissue-dependent responses in hormone-responsive tissues and organs, exhibiting variations in estrogenic activity in preclinical models of postmenopausal reproductive tissues that may improve postmenopausal women’s health (eg, prevention and treatment of breast cancer, osteoporosis, and vulvar and vaginal atrophy).

Methods: This literature review investigates whether preclinical data predicted the clinical effects of ospemifene on female reproductive and urinary tract tissues and compares these findings with the specific vaginal effects of other estrogen receptor agonists/antagonists (tamoxifen, raloxifene, and bazedoxifene) in preclinical and clinical studies. Lasofoxifene, although not currently available, is included because of its unique effects on vaginal tissue.

Results: The response of endometrial and vaginal tissues to estrogen receptor agonists/antagonists can be differentiated using transvaginal ultrasound, endometrial histopathology, cytologic examination of vaginal smears, assessment of physical changes in the vagina, and relief of symptoms associated with vulvar and vaginal atrophy (such as dyspareunia).

Conclusions: Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists (eg, tamoxifen, raloxifene, and bazedoxifene) with no short-term concerns about endometrial safety (based on endometrial hyperplasia, carcinoma, endometrial spotting, and endometrial bleeding).

Key Words: Dyspareunia – Endometrium – Vulvar and vaginal atrophy – Urinary tract – Estrogen receptor agonist/antagonist – Selective estrogen receptor modulator.

Up to 50% of postmenopausal women experience vulvar and vaginal atrophy (VVA), a long-term condition caused by estrogen deficiency that is characterized by histologic vaginal changes such as epithelial thinning, decreased squamous cell maturation, and increased pH; VVA symptoms negatively impact women’s quality of life. VVA is thought to be a progressive condition that does not resolve without treatment. In postmenopausal women, estrogen deficiency also adversely affects other tissues (eg, musculoskeletal, uterine, and urinary tract tissues, increasing the risk for osteoporosis, fracture, recurrent urinary tract infection, and urinary incontinence).

Received July 17, 2014; revised and accepted September 9, 2014.

From the 1Eastern Virginia Medical School, Norfolk, VA; 2University of Texas Southwestern Medical Center, Dallas, TX; 3University of Virginia, Charlottesville, VA; 4Yale School of Medicine, New Haven, CT; and 5Endochute Consultants, Malvern, PA.

Funding/support: Medical writing support was provided by Craig D. Albright, PhD (Complete Publication Solutions LLC) and funded by Shionogi Inc (Florham Park, NJ).

Financial disclosure/conflicts of interest: D.F.A. serves as consultant to Shionogi Inc, Agile Therapeutics, AbbVie, Bayer Healthcare, CHEMO, Endoceutics, HRA Pharma, and TEVA, and serves at the speakers bureau for Pfizer, Shionogi Inc, Agile Therapeutics, and Merck. B.R.C. serves at the speakers bureau for Shionogi Inc, Pfizer, and Noven Pharmaceuticals Inc, and has received grants/research support (funds to the University of Texas) from AbbVie. In the past 12 months, J.V.P. has served as consultant (fees to the University of Virginia) to Pfizer Inc, Noven Pharmaceuticals Inc, Novo Nordisk, DepoMed, Shionogi, and TherapeuticsMD; has received grants/research support (funds to the University of Virginia) from DepoMed, Bionova, TherapeuticsMD, and Endoceutics; has received travel funds from Pfizer Inc, Noven Pharmaceuticals Inc, DepoMed, Novo Nordisk, Endoceutics, and Shionogi; and has received editorial writing support from Pfizer Inc, Shionogi, and Noven Pharmaceuticals Inc. H.S.T. has served as consultant to Pfizer, AbbVie, Medistem, and Ovascience. G.D.C. has served as consultant to pharmaceutical companies including, but not limited to, Shionogi Inc and TherapeuticsMD. G.D.C. is a former employee of Wyeth and Pfizer.

Address correspondence to: David F. Archer, MD, Eastern Virginia Medical School, Second Floor, 601 Colley Avenue, Norfolk, VA 23507. E-mail: archerdf@evms.edu

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received: September 9, 2014
 Revised: September 9, 2014
 Accepted: September 9, 2014

© 2014 by The North American Menopause Society
Low-dose vaginal estrogen-based prescription treatments and nonprescription vaginal lubricants and moisturizers are currently recommended as first-line treatment of VVA when only vaginal symptoms are present. Vaginal estrogen interventions restore vaginal physiology and improve the vaginal microbiome, providing relief of bothersome symptoms such as vaginal dryness and dyspareunia. Compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, have been developed to elicit benefits in target tissues while minimizing off-target adverse effects. Ospemifene is an estrogen receptor agonist/antagonist (ERAA) that was recently approved by the US Food and Drug Administration for the treatment of moderate to severe dyspareunia, a symptom of VVA caused by menopause. Ospemifene has been recommended as an option for therapy in the 2013 North American Menopause Society guidelines for the treatment of symptomatic VVA.

The objectives of this review are to describe the effects of ospemifene on female reproductive and urinary tract tissues and to assess the utility of preclinical models in predicting ERAA effects on end organs in humans. The preclinical and clinical findings for ospemifene and several other ERAAs, including tamoxifen, raloxifene, bazedoxifene (in combination with conjugated estrogens [CE]), and lasofoxifene, will be described.

**SEARCH METHODOLOGY**

Relevant articles in English were identified via a search of PubMed from 1990 to 2013 using the search string “(Selective Estrogen Receptor Modulator OR SERM) AND (Vagina OR Vulvar OR Endometrium OR Uterus OR Uterine OR Bone OR Breast OR Brain OR Urinary OR Urogenital),” including clinical trials, guidelines, meta-analyses, and systematic reviews but excluding case reports and letters. Additional references of interest were identified by manual review of cited reference lists and PubMed searches of individual ERAAs.

**ERAA MECHANISM OF ACTION**

Biological effects of ERAA’s are mediated through binding and activation of intracellular estrogen receptors (specifically estrogen receptor-α [ER-α], estrogen receptor-β [ER-β], or both) that function as nuclear ligand–inducible transcription factors. After ligand binding, a conformational change in estrogen receptor leads to recruitment of coregulator proteins, transcription factors, and chromatin remodeling factors responsible for regulation of gene expression. Importantly, ERAAs may exert a mix of agonist, antagonist, or neutral biological effects (Tables 1 and 2) because the response pathway in a given tissue depends on estrogen receptor subtype (eg, ER-α–selective vs ER-β–selective ERAAs), the structure and shape of the ligand-receptor complex, and the functional cooperation of the gene promoter with cell type–specific transcriptional coactivators (mimicking estrogenic activity) and corepressors (suppressing estrogenic activity; Fig.). As agonist/antagonist effects of ERAAs depend on dose, relative doses in animals and humans also should be considered when assessing the prediction of clinical effects from preclinical data.

Although ERAAs exhibit potentially beneficial effects on a number of tissues that are important for postmenopausal women’s health, we will principally consider the effects of each ERAA on the vaginal epithelium; on uterine, endometrial, and bone.

**TABLE 1. Effects of selected ERAAs on target tissues in animals**

| ERAA       | Chemical structure | Uterine weight          | Endometrium                  | Vagina                  | Breast                  | Bone                      |
|------------|--------------------|-------------------------|------------------------------|-------------------------|-------------------------|---------------------------|
| Ospemifene | ![Chemical structure](image) | Neutral<sup>11,12</sup> Partial agonist<sup>13,14</sup> | Neutral<sup>12</sup> Partial agonist<sup>11</sup> | Agonist<sup>13</sup> | Antagonist<sup>14,17</sup> | Neutral (OCF)<sup>18</sup> Antagonist (BR)<sup>14</sup> Agonist (BF)<sup>19</sup> |
| Tamoxifen  | ![Chemical structure](image) | Agonist<sup>11,20,23</sup> | Neutral<sup>20</sup> Agonist<sup>26,28</sup> | Agonist<sup>24</sup> | Antagonist<sup>25</sup> | Agonist (BF)<sup>19,21</sup> Antagonist (OCF)<sup>18</sup> |
| Raloxifene | ![Chemical structure](image) | Neutral<sup>11,20,23,27,30,31</sup> Partial agonist<sup>3,36</sup> | Neutral<sup>20,27,32</sup> Partial agonist<sup>11,31,36</sup> | Neutral<sup>13</sup> | Antagonist<sup>24,35</sup> | Neutral (OCF)<sup>19</sup> Agonist (BF)<sup>32,37</sup> Antagonist (BR) |
| Bazedoxifene | ![Chemical structure](image) | Partial agonist<sup>38</sup> Antagonist<sup>42</sup> | Neutral<sup>39</sup> Antagonist<sup>42</sup> | ND | Antagonist<sup>40,41</sup> | Agonist<sup>38</sup> |

ERAA, estrogen receptor agonist/antagonist; OCF, osteoclast formation; BR, bone resorption; BF, bone formation; ND, no data.
and ovarian tissues; and on the female urinary tract to differentiate those agents that are most likely to be beneficial without posing short-term or long-term safety concerns.

**VAGINAL EFFECTS**

**Preclinical data**

Ospemifene (10 mg/kg/d for 2 wk) had a more pronounced effect than raloxifene (10 mg/kg/d) on increasing the thickness and mucification of the vaginal epithelium in a commonly used ovariectomized rat model. Similar morphologic changes were observed with continuous subcutaneous tamoxifen infusion (150 μg/d for 2 wk). Systemic CE 0.1 mg/kg/day resulted in higher vaginal epithelium maturation scores, but raloxifene (1 mg/kg/d for 35 d) did not, suggesting that raloxifene has no clear estrogenic effect on the vaginal epithelium, unlike ospemifene and tamoxifen.

**Clinical data**

The effects of ospemifene on reproductive tissues in postmenopausal women have been investigated in three phase 3 multicenter, randomized, double-blind, clinical trials. In one 12-week study, 826 women with a low vaginal maturation index (MI; ie, ≤5% superficial cells on vaginal smear) and a vaginal pH higher than 5.0 were randomized to receive ospemifene or placebo.

**TABLE 2. Effects of selected ERAAs on target tissues in humans**

| ERAA              | Endometrium                        | Vagina                                      | Breast                                      | Bone                                         |
|-------------------|------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|
| Ospemifene        | Partial agonist<sup>43-46</sup>    | Agonist<sup>43-46</sup>                    | Neutral (limited data)<sup>43-46</sup>      | Agonist (limited data)<sup>47,48</sup>       |
|                   | • Up to 52-wk RCT                   | • Up to 52-wk RCT                          | • Up to 52-wk RCT                          | • 3-mo RCT                                   |
|                   | • Slight † in thickness from BL by TVU | • SS † in superficial cells                | • No clinically significant abnormalities by mammography | • Positive effects of bone turnover on biomarkers |
|                   | • Generally no histologic changes from BL | • SS † in parabasal cells                  | • No reports of cancer during these RCTs<sup>a</sup> |                                              |
|                   | • No reports of cancer              | • SS † in pH                               |                                              |                                              |
|                   | • P < 0.001 for all vs PBO          | • P < 0.001                                |                                              |                                              |
| Tamoxifen         | Agonist<sup>50-51</sup>            | Meta-analysis of four trials               | Antagonist<sup>11</sup>                     | Agonist<sup>5</sup>                         |
|                   | • Meta-analysis of four trials      | • SS † in cancer (P < 0.001) vs PBO         | • SS † in cancer vs PBO (P < 0.0001)        | • SS † in lumbar spine BMD vs PBO (P < 0.001) |
|                   | • † in thickness<sup>b</sup>        | • SS † in MI across 24 mo vs controls (P < 0.0001) | • SS † in MI across 24 mo vs controls (P < 0.0001) | • SS † in serum osteocalcin from BL vs PBO (P < 0.001) |
| Raloxifene        | Neutral or antagonist<sup>11,54-58</sup> | • Up to 6-9 mo CT                          | Antagonist<sup>11</sup>                     | Agonist<sup>60,61</sup>                      |
|                   | • Meta-analysis of three trials     | • No difference in thickness by TVU and in incidence of bleeding vs controls | • SS † in MI across 24 mo vs controls (P < 0.0001) | • SS † in lumbar spine BMD vs PBO (P < 0.05) |
|                   | • No difference in thickness by TVU and in incidence of bleeding vs controls | • No difference in VMV or parabasal, intermediate, or superficial cells by smear vs controls | • SS † in all breast cancers (P < 0.0001) | • SS † in bimarkers of bone turnover vs PBO or BL (P < 0.05) |
| Bazedoxifene (monotherapy) | Antagonist<sup>62</sup> | • 7-7 y RCT | Antagonist<sup>63</sup> | Agonist<sup>60,68</sup> |
|                   | • No difference in thickness by TVU and in incidence of hyperplasia vs PBO | • 12-wk RCT | • No † in density by mammography vs PBO | • Up to 5-y RCT |
|                   | • SS † in incidence of cancer vs PBO (P = 0.02) | • Little change in superficial cells vs BL; parabasal cells increased; intermediate cells decreased<sup>c</sup> | • No difference in cancer rates or pain vs PBO | • SS † in incidence of new vertebral fractures vs PBO (P < 0.05) |
|                   | • No difference in thickness by TVU and in incidence of hyperplasia vs PBO | • No difference in superficial cells vs BL; parabasal cells increased; intermediate cells decreased<sup>d</sup> | • No difference in cancer rates or pain vs PBO | • SS † in lumbar spine BMD vs PBO (P ≤ 0.023) |
|                   | • SS † in incidence of cancer vs PBO (P = 0.02) | • No difference in superficial cells vs BL; parabasal cells increased; intermediate cells decreased<sup>d</sup> | • No difference in cancer rates or pain vs PBO | • SS † in serum osteocalcin/CTX vs PBO (P ≤ 0.009) |

ERAA, estrogen receptor agonist/antagonist; RCT, randomized clinical trial; (†) increase; BL, baseline; (†) decrease; TVU, transvaginal ultrasound; SS, statistically significant; PBO, placebo; MI, maturation index; BMD, bone mineral density; CT, clinical trial (randomized or not); VMV, vaginal maturation value; CTX, type 1 collagen C-telopeptide.

<sup>a</sup>Total N equals 1,384.

<sup>b</sup>One 2-year RCT and one 5-year longitudinal study (median treatment time, 24 mo).<sup>49,50</sup>

<sup>c</sup>No statistical testing was performed versus PBO.<sup>63</sup>
Ligand-induced conformational change depending on ERAA and receptor subtype (ERα or ERβ)
Dimerization of ligand-ER complexes and binding to DNA

CoA or CoR binding depending on tissue type and ligand-ER complex conformation

Transcription
Agonist action

No transcription
Antagonist action

FIG. Estrogen receptor agonist/antagonist mechanism of action via binding to the ER-α or ER-β receptor and eliciting specific nuclear coactivators and corepressors. ERAA, estrogen receptor agonist/antagonist; ER, estrogen receptor; CoA, coenzyme A.
with CE 0.625 or 0.45 mg/day significantly increased superficial cells, decreased parabasal cells, and improved vaginal dryness, compared with placebo, on week 12 (P < 0.01, P < 0.001, and P < 0.05, respectively).63 Bazedoxifene 20 mg/day with CE 0.625 or 0.45 mg/day was associated with a significant improvement in ease of lubrication (assessed with the Arizona Sexual Experiences scale) from baseline to week 12 compared with placebo (P < 0.01) or bazedoxifene 20 mg alone (P < 0.001).

Treatment with raloxifene monotherapy does not improve VVA, in contrast with ospemifene and bazedoxifene/CE. Raloxifene (60 mg/d) in postmenopausal women treated for 3 to 6 months had no effect on vaginal MI.54,59 Raloxifene monotherapy for 6 months in postmenopausal women with osteoporosis did not affect the vaginal epithelium.59 Raloxifene alone also did not increase vaginal bleeding (endometrial), spotting, or discharge even after administration for 3 years;55 thus, it seems to have a safe vaginal profile. Although raloxifene, in combination with a local estrogen, is not approved for the treatment of VVA, the addition of raloxifene with vaginal CE cream in a 3-month study and of an estradiol ring in a 6-month trial did not counteract the local symptomatic or objective estrogenic effects of vaginal estrogens.80,81

Postmenopausal women with breast cancer who received tamoxifen for 2 years showed significant improvement in vaginal MI compared with control groups but also had an increased prevalence of endocervical hyperplasia.52 In the ATAC (‘Arimidex,’ Tamoxifen, Alone or in Combination) trial, postmenopausal women treated with tamoxifen for 5 years reported vaginal dryness (9.1%) and dyspareunia (8.1%), although these rates were lower than those reported with the comparator anastrozole (18.5% and 17.3%, respectively).82 In summary, the positive effects of ospemifene on vaginal tissue differ from those of other ERAAs, such as the mixed effects of tamoxifen, the neutral effects of raloxifene, and the mild negative effects of bazedoxifene alone.

**UTERINE, ENDOMETRIAL, AND OVARIAN EFFECTS**

**Preclinical data**

Studies in rodents suggest that the effects of ERAAs on uterine weight are dose-dependent and time-dependent. In mice, a single dose of tamoxifen 3 mg/kg significantly increased uterine weight similar to estradiol (138% and 141% of ovariec tomized control, respectively) at 16 hours after administration, but ospemifene and raloxifene (3 mg/kg each) had no effects on uterine weight at the same time point.11 Ospemifene (0.1-10 mg/kg/d for 28 d) caused dose-dependent increases (significant increases at 0.3-10 mg/kg) in uterine weight compared with raloxifene (3 mg/kg for 14 d) in ovariec tomized rats.14 Even so, the agonist effect of ospemifene (0.1-10 mg/kg) on uterine weight was only 37% of the increase noted with estradiol, consistent with the lower binding affinity of ospemifene, compared with estradiol, for ER-α (Table 3).13 The dose-dependent increases in vaginal and uterine epithelial thickness with ospemifene were accompanied by morphohistologic changes in the vaginal epithelium (eg, mucification and vacuolization).75 Bazedoxifene also exhibited a lower in vitro binding affinity, compared with estradiol, for both ER-α and ER-β; raloxifene inhibited ER-α to a similar degree as estradiol but was a weaker inhibitor of ER-β (Table 3).38 When administered alone for 8 weeks, bazedoxifene decreased uterine weight in mice and exhibited no uterotrophic effects on a postmenopausal primate model.39,42

In ovariec tomized rats, tamoxifen caused a dose-dependent (1-1,000 μg/kg) increase in uterine weight (concentration producing 50% activity [EC50], 33.7 μg/kg) at 72 hours, which was accompanied by increased luminal epithelial thickness (at doses 30-1,000 μg/kg), stromal cell hypertrophy (10-1,000 μg/kg), epithelial hypertrophy and hyperplasia (30-1,000 μg/kg), increased glandular secretory activity (30-1,000 μg/kg), and mild edema (100-1,000 μg/kg).26 A single dose (3 mg/kg) of tamoxifen, raloxifene, or ospemifene resulted in increased proliferation of luminal and glandular endometrial epithelial cells in ovariec tomized rats.11 In addition, in a postmenopausal primate model, administration of tamoxifen for 4 months caused a pronounced increase in endometrial thickness (similar to estradiol) that was accompanied by stromal fibrosis.83

Unlike the estrogenic response elicited by tamoxifen in the uterus, several preclinical studies showed that raloxifene did not significantly increase myometrial or stromal thickness or cause endometrial hyperplasia20,27,32 even when administered for up to 2 years.28

Administration of bazedoxifene for 8 weeks caused a significant decrease in epithelial thickness and endometrial gland formation in the mouse uterus, consistent with previously described antagonistic effects on uterine weight.42 Moreover, in

**TABLE 3. Binding potencies of estradiol and selected ERAAs for ER-α and ER-β receptors**

| Study | Compound | IC50 (nM) |
|-------|----------|----------|
|       |          | ER-α     | ER-β     |
| Unkila et al13 | Ospemifene | 827      | 1,633    |
|        | Estradiol | 6.8      | 91.1     |
| Komm et al38  | Bazedoxifene | 26      | 99    |
|        | Estradiol | 3.2      | 3.6      |
|        | Raloxifene | 2.4      | 43      |

ERAA, estrogen receptor agonist/antagonist; ER-α, estrogen receptor-α; ER-β, estrogen receptor-β; IC50, concentration producing 50% inhibition.
In the same study, bazedoxifene suppressed endometrial proliferation and caused regression of experimentally induced endometriosis. Interestingly, bazedoxifene (20 mg/d) with systemic conjugated equine estrogens (0.45 mg/d) for 20 months inhibited the development of endometrial hyperplasia and ER-α target genes in a postmenopausal primate model in which bazedoxifene alone showed no uterotrophic effects.39

Preclinical studies in rodents showed that tamoxifen (0.03 and 0.2 mg/kg/d for 2-4 wk) and raloxifene (75 and 365 mg/kg/d for 6 mo), but not bazedoxifene (3 mg/kg/d for 8 wk), induced the formation of ovarian cysts.42,84,85 Ospemifene (3, 30, and 300 mg/kg/d for 26 wk) increased the number of ovarian cysts in rats. Two studies of ospemifene (100, 500, and 1,250 mg/kg/d for 4 wk; 15, 50, and 150 mg/kg/d for 39 wk) in primates demonstrated an elevated incidence of ovarian cysts in all dose groups. As discussed subsequently, however, preclinical findings of ovarian cysts did not always translate into clinical findings.

Clinical data: effects on the endometrium

The long-term risk of developing endometrial hyperplasia is another concern with the use of ERAAs. Postmenopausal women (N = 826) randomized to receive ospemifene (30 and 60 mg/d) or placebo for 12 weeks exhibited modest changes from baseline in endometrial thickness (0.42 and 0.72 mm, respectively) compared with placebo (0.02 mm).43 These outcomes were independently confirmed in a second 12-week randomized study that compared ospemifene 60 mg/day with placebo.45 The effects of ospemifene 60 mg/day on endometrial thickness are summarized in Table 4. Phase 3 clinical trials found no evidence of endometrial hyperplasia or carcinoma

### TABLE 4. Endometrial thickness in women treated with ospemifene 60 mg/day versus placebo in phase 2 and phase 3 randomized, double-blind, placebo-controlled studies

| Characteristic                              | Placebo (n = 543) | n | Ospemifene 60 mg/d (n = 851) | n |
|---------------------------------------------|-------------------|---|----------------------------|---|
| Endometrial thickness, mean (SD), mm        |                   |   |                            |   |
| Baseline                                    | 2.2 (0.8)         | 538| 2.1 (0.8)                  | 847|
| 12 wk                                       | 2.2 (1.2)         | 367| 2.6 (1.5)                  | 641|
| 6 mo                                        | 2.1 (1.1)         | 92 | 2.6 (1.5)                  | 371|
| 12 mo                                       | 2.1 (1.0)         | 85 | 2.8 (1.4)                  | 345|
| Change from baseline in endometrial thickness, mean (SD), mm |       |   |                            |   |
| 12 wk                                       | 0.1 (1.2)         | 365| 0.5 (1.5)                  | 640|
| 6 mo                                        | <0.1 (1.3)        | 92 | 0.6 (1.6)                  | 370|
| 12 mo                                       | 0.1 (1.2)         | 85 | 0.8 (1.5)                  | 344|
| Postbaseline endometrial thickness, n (%)   |                   |   |                            |   |
| Any time postbaseline                       | 458              |   |                            | 771|
| ≥4 mm                                       | 29 (6.3)          | 140| (18.2)                     |    |
| ≥5 mm                                       | 14 (3.1)          | 69 | (9.0)                      |    |
| ≥8 mm                                       | 2 (0.4)           | 12 | (1.6)                      |    |
| Last observation*                           | 458              |   |                            | 771|
| ≥4 mm                                       | 20 (4.4)          | 98 | (12.7)                     |    |
| ≥5 mm                                       | 12 (2.6)          | 51 | (6.6)                      |    |
| ≥8 mm                                       | 1 (0.2)           | 9 |  (1.2)                     |    |

Data presented here are from the Integrated Summary of Safety conducted by Shionogi Inc. All authors had access to this report, and part of the data was presented at the International Menopause Society 14th World Congress on Menopause [Constantine G, Goldstein S, Graham S. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. In: International Menopause Society 14th World Congress on Menopause; May 1-4, 2014; Cancun, Mexico].

*Within 14 days of the last dose of the study drug.

the same study, bazedoxifene suppressed endometrial proliferation and caused regression of experimentally induced endometriosis. Interestingly, bazedoxifene (20 mg/d) with systemic conjugated equine estrogens (0.45 mg/d) for 20 months inhibited the development of endometrial hyperplasia and ER-α target genes in a postmenopausal primate model in which bazedoxifene alone showed no uterotrophic effects.39

Preclinical studies in rodents showed that tamoxifen (0.03 and 0.2 mg/kg/d for 2-4 wk) and raloxifene (75 and 365 mg/kg/d for 6 mo), but not bazedoxifene (3 mg/kg/d for 8 wk), induced the formation of ovarian cysts.42,84,85 Ospemifene (3, 30, and 300 mg/kg/d for 26 wk) increased the number of ovarian cysts in rats. Two studies of ospemifene (100, 500, and 1,250 mg/kg/d for 4 wk; 15, 50, and 150 mg/kg/d for 39 wk) in primates demonstrated an elevated incidence of ovarian cysts in all dose groups. As discussed subsequently, however, preclinical findings of ovarian cysts did not always translate into clinical findings.

Clinical data: effects on the endometrium

The long-term risk of developing endometrial hyperplasia is another concern with the use of ERAAs. Postmenopausal women (N = 826) randomized to receive ospemifene (30 and 60 mg/d) or placebo for 12 weeks exhibited modest changes from baseline in endometrial thickness (0.42 and 0.72 mm, respectively) compared with placebo (0.02 mm).43 These outcomes were independently confirmed in a second 12-week randomized study that compared ospemifene 60 mg/day with placebo.45 The effects of ospemifene 60 mg/day on endometrial thickness are summarized in Table 4. Phase 3 clinical trials found no evidence of endometrial hyperplasia or carcinoma

### TABLE 5. AEs related to uterine polyp and vaginal bleeding in phase 2 and phase 3 randomized, double-blind, placebo-controlled studies of ospemifene 60 mg/day

| Preferred term                              | Placebo n | Ospemifene 60 mg/d | n |
|---------------------------------------------|-----------|--------------------|---|
| Women with intact uterus                    |           |                    |   |
| Any uterine polyp TEAE, n (%)               | 1 (0.2)   | 5 (0.6)            |   |
| Uterine polyp                               | 1 (0.2)†  | 5 (0.6)†           |   |
| Any vaginal bleeding and/or spotting TEAE, n (%)| 5 (0.9)  | 10 (1.2)           |   |
| Vaginal hemorrhage                          | 5 (0.9)   | 7 (0.8)            |   |
| Coital bleeding                             | 0         | 1 (0.1)            |   |
| Irregular menstruation                      | 0         | 1 (0.1)            |   |
| Metrorrhagia                                | 0         | 1 (0.1)            |   |
| Women without intact uterus                 |           |                    |   |
| Any vaginal bleeding and/or spotting TEAE, n (%)| 0        | 1 (0.3)            |   |
| Vaginal hemorrhage                          | 0         | 1 (0.3)            |   |

Data presented here are from the Integrated Summary of Safety conducted by Shionogi Inc. All authors had access to this report, and part of the data was presented at the International Menopause Society 14th World Congress on Menopause [Goldstein S, Archer D, Graham S. Safety of oral ospemifene in phase 2/3 placebo-controlled clinical trials. In: International Menopause Society 14th World Congress on Menopause; May 1-4, 2014; Cancun, Mexico].

AE, adverse event; TEAE, treatment-emergent adverse event.

*All uterine polyps were reported in a single study (incidence with placebo, 1/62 [1.6%]; incidence with ospemifene, 5/364 [1.4%])46; none were reported in the other studies included in phase 2/phase 3 analysis. Only one polyp (in the ospemifene group) was confirmed on further expert review, whereas the rest were considered artifacts.46

†Women with more than 1 TEAE that coded for the same preferred term were counted once for that preferred term.

Menopause, Vol. 22, No. 7, 2015 791

OSPEMIFENE REPRODUCTIVE/URINARY TRACT EFFECTS

Copyright © 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.
in endometrial biopsies of postmenopausal women treated with ospemifene for 12 weeks.\textsuperscript{43,44} Moreover, treatment with ospemifene for 52 weeks resulted in a low incidence (0.3%) of endometrial hyperplasia but no cases of carcinoma in women (n = 267) who had biopsies on week 52.\textsuperscript{46} The endometrial safety profile of ospemifene 60 mg/day is summarized in Table 5.

Raloxifene, which is approved for the treatment and prevention of osteoporosis in postmenopausal women and for reduction of the risk of invasive breast cancer,\textsuperscript{56} had no effect on endometrial thickness or proliferation compared with baseline when administered at a dose of 60 mg/day for 3 months.\textsuperscript{54} Moreover, vaginal bleeding and spotting were not elevated in women who were treated with raloxifene 60 mg/day for up to 5 years (2.9%-3.3%) compared with untreated women (1.9%-3.6%).\textsuperscript{55,57,58} Consistent with the lack of uterotrophic effects of raloxifene observed in preclinical studies (reviewed previously), there was no evidence of increased endometrial hyperplasia or carcinoma in postmenopausal women administered raloxifene for up to 8 years, although uterine polyps were significantly more common than with placebo.\textsuperscript{56}

Bazedoxifene has a favorable long-term endometrial safety profile. In a phase 3 study, bazedoxifene (20 or 40 mg/d) for 7 years had minimal effects on endometrial thickness (−0.11 mm for bazedoxifene vs 0.07 mm for placebo) and endometrial hyperplasia (0.1% for all groups).\textsuperscript{62} Similar to ospemifene, bazedoxifene (20 and 40 mg/d) for 7 years produced a lower rate of endometrial carcinoma compared with placebo (0.1% vs 0.4%; \textit{P} = 0.020) and had negligible effects on endometrial hyperplasia (0.1% for both groups).\textsuperscript{87}

The favorable endometrial safety profiles of ospemifene, bazedoxifene, and raloxifene are distinct from that of tamoxifen. Results from the ATAC breast cancer prevention trial showed that tamoxifen treatment caused a pronounced increase (from 3.8 mm at baseline to 7.0 mm after 2 y) in endometrial thickness.\textsuperscript{49} Importantly, such effects persisted for approximately 3 years after the end of treatment.\textsuperscript{50} Tamoxifen therapy (20-30 mg/d for approximately 3 y) was associated with higher incidences of endometrial hyperplasia (35.7% vs 5.6%; \textit{P} < 0.0001) and endometrial cancer (21.5% vs 0.9%; \textit{P} < 0.0001) in postmenopausal women with breast cancer who had gynecologic symptoms (vaginal bleeding or spotting), compared with similar participants without such symptoms.\textsuperscript{88} A meta-analysis of nine breast cancer prevention trials found a higher incidence of endometrial cancer (hazard ratio, 2.18; 95% CI, 1.39-3.42; \textit{P} = 0.001) during the first 5 years of follow-up with tamoxifen (ie, Marsden, International Breast Cancer Intervention Study-I, National Surgical Adjuvant Breast and Bowel Project, Prevention-I, and Italian trials) but no increased risk of endometrial cancer with raloxifene (ie, Multiple Outcomes of Raloxifene Evaluation/Continuing Outcomes Relevant to Evista, Raloxifene Use for The Heart, Study of Tamoxifen and Raloxifene, and Postmenopausal Evaluation and Risk Reduction With Lasofoxifene trials).\textsuperscript{51} In fact, the Study of Tamoxifen and Raloxifene P2 study (an update to the Study of Tamoxifen and Raloxifene) found that the relative risks (RRs) for endometrial hyperplasia (RR, 0.19; 95% CI, 0.12-0.29) and endometrial cancer (RR, 0.55; 95% CI, 0.36-0.83; \textit{P} = 0.003) with raloxifene (60 mg/d) were lower than those with tamoxifen (20 mg/d) across 5 years.\textsuperscript{89} The endometrial safety profile of the ERAAs contrasts with that of CE 0.625 mg/day alone (endometrial hyperplasia rate of 21% after 1 y).\textsuperscript{90} The risk of endometrial cancer is greatly elevated with longer use of unopposed or high-dose CE (overall risk ratio, 7.6; risk ratio with ≥7 y of use, 13.9).\textsuperscript{91}

**Clinical data: effects on the ovaries**

Consistent with preclinical observations, ovarian cysts were detected in 6.3% to 14.3% of postmenopausal women administered tamoxifen therapy for breast cancer.\textsuperscript{82,92} However, no evidence of increased ovarian cyst formation was detected in postmenopausal women receiving bazedoxifene (20 or 40 mg/d) or raloxifene (60 mg/d) for 3 years.\textsuperscript{94} In pivotal ospemifene studies, only one participant (0.1%; n = 1,242) developed ovarian cysts, which is well within the annual rate (2.6%) of spontaneous ovarian cyst formation found among postmenopausal women in a large, prospective, multicenter, cohort study.\textsuperscript{95} In summary, rates of ovarian cyst formation with ospemifene, bazedoxifene, and raloxifene are within the background incidence rates for postmenopausal women, but may be increased with tamoxifen.

**URINARY TRACT EFFECTS**

**Preclinical data**

Varied effects of ERAAs on the urinary tract have been reported in preclinical studies. The urinary tract effects of ospemifene and raloxifene were assessed in ovariectomized rats using estradiol and placebo controls (data on file at Shionogi Inc). There were no statistically significant between-treatment differences in bladder pressure, flow rate, micturition time, amount of residual urine, or bladder capacity, suggesting that ospemifene and raloxifene had no effect on urodynamics. In a rat model of urinary incontinence caused by trauma during parturition, treatment with raloxifene (1 mg/kg/d) or 17β-estradiol (0.1 mg/kg/d) resulted in greater detrusor overactivity and urethral relaxation incontinence, compared with controls, suggesting that raloxifene and estrogen may worsen voiding patterns.\textsuperscript{86} Others found no significant effect of raloxifene (1 mg/kg/d) or 17β-estradiol (0.01 mg/kg/d) on voiding patterns in the same rat model, suggesting a lack of specificity for this model.\textsuperscript{97} In ovariectomized rats, raloxifene (750 μg/d for 30 d) significantly increased distal urethral epithelial thickness compared with vehicle control, suggesting a potential beneficial effect of raloxifene for postmenopausal urinary incontinence.\textsuperscript{98} Additional studies are necessary to fully elucidate the effects of raloxifene on the urinary tract. Tamoxifen improved impaired bladder capacity and compliance in an animal model of chronic inflammatory bladder disease, in which ER-β was significantly decreased in a diseased bladder compared with a control bladder.\textsuperscript{99}

**Clinical data**

Although ERAAs have been reported to adversely affect the pelvic floor and to cause incontinence, urodynamics data are
OSPEMIFENE REPRODUCTIVE/URINARY TRACT EFFECTS

TABLE 6. TEAEs of the reproductive and urinary tracts in women (≥1%) treated with ospemifene 60 mg/day versus placebo in phase 2 and phase 3 randomized, double-blind, placebo-controlled studies

| Preferred term                  | Placebo (n = 924) | Ospemifene 60 mg/d (n = 1,242) |
|--------------------------------|------------------|--------------------------------|
| Any TEAE, n (%)*               | 496 (53.7)       | 840 (67.6)                     |
| Urinary tract infection        | 44 (4.8)         | 81 (6.5)                       |
| Vaginal discharge              | 4 (0.4)          | 55 (4.4)                       |
| Vulvovaginal candidiasis       | 5 (0.5)          | 53 (4.3)                       |
| Vulvovaginal mycotic infection | 5 (0.5)          | 38 (3.1)                       |
| Cystitis                       | 6 (0.6)          | 23 (1.9)                       |
| Genital discharge              | 1 (0.1)          | 18 (1.4)                       |
| Vulvovaginal pruritus          | 7 (0.8)          | 18 (1.4)                       |
| Urinary tract infection bacterial | 6 (0.6)       | 17 (1.4)                       |
| Vaginal infection              | 6 (0.6)          | 13 (1.0)                       |
| Vulvovaginal dryness           | 1 (0.1)          | 13 (1.0)                       |

Data presented here are from the Integrated Summary of Safety conducted by Shionogi Inc. All authors had access to this report, and part of the data was presented at the International Menopause Society 14th World Congress on Menopause [Goldstein S, Archer D, Graham S. Safety of oral ospemifene in phase 2/3 placebo-controlled clinical trials. In: International Menopause Society 14th World Congress on Menopause; May 1-4, 2014; Cancun, Mexico]. TEAE, treatment-emergent adverse event.

*Women with more than one TEAE that coded for the same preferred term were counted once for that preferred term.

limited, and no published study has identified clear effects. The percentage of participants with improved urinary symptoms (eg, frequent urination, urine leakage, and difficulty in voiding) was similar among the ospemifene 30 mg, ospemifene 60 mg, and placebo groups in two 12-week studies. An integrated assessment of safety in phase 2 and phase 3 clinical trials showed that ospemifene 60 mg/day elicited low incidences of vaginal and urinary adverse outcomes (eg, discharge, infection, pruritus, dryness, urinary tract infection, and cystitis; Table 6). The rates of urinary tract infection, vaginal discharge, vulvovaginal candidiasis, and vulvovaginal mycotic infection seemed greater with ospemifene treatment than with placebo, although the absolute incidences were low. The low incidences of urinary tract infections and cystitis observed with ospemifene are consistent with the reduction in vaginal pH, indicating increased vaginal Lactobacillus colonization with reduction in the incidence of Escherichia coli in the vagina. More studies are necessary to delineate the effects of ospemifene on the urinary tract.

Discontinued ERAAs
ERAAs that entered clinical development but failed to advance include compounds that failed to meet planned endpoints (eg, arzoxifene) and compounds that produced unacceptable adverse effects such as urinary incontinence and pelvic organ prolapse (eg, levomeloxifene and lasofoxifene). Lasofoxifene demonstrated clinical efficacy for postmenopausal osteoporosis in phase 3 trials but was associated with gynecologic safety concerns (vaginal bleeding, increased endometrial thickness, and increased endometrial polyps).

DISCUSSION
ERAAs are structurally heterogeneous compounds that interact with estrogen receptors, which function as nuclear ligand–inducible transcription factors and elicit diverse biological responses in hormone-responsive target tissues. The clinical value of ERAAs stems from their potential to exert favorable effects on hormone-related postmenopausal conditions (eg, reduction in breast cancer, prevention and treatment of osteoporosis, and relief of VVA for some ERAAs) while minimizing unfavorable effects on the urogenital system, endometrium, breast, ovary, bone, and central nervous system. However, a twofold increase in the risk of venous thromboembolism with ERAAs remains a concern for this drug class. The preclinical studies reviewed demonstrate the differential activity of ERAAs in female reproductive and urinary tract tissues and are reasonably predictive of the clinical response of compounds that were successful in clinical trials. Thus, compared with tamoxifen, the less pronounced estrogenic effects of ospemifene, raloxifene, and bazedoxifene on uterine weight and endometrial thickness in animals reflect the endometrial safety profile seen in clinical studies of postmenopausal women. In addition, the increased vaginal epithelial thickness and mucification observed in preclinical studies of ospemifene, but not raloxifene, reflect the improvement in VVA observed in clinical studies of ospemifene. Ospemifene improves vaginal MI and relieves VVA-associated symptoms, unlike raloxifene and bazedoxifene alone. Clinical data on the effects of ERAAs on the breast (other than the effects of tamoxifen and raloxifene), cardiovascular system (including the risk of venous thromboembolism), bone, and brain are not the focus of this article, and available data are reviewed elsewhere; characterization of hot flashes with ospemifene will be the topic of a future publication.

Endometrial safety is a major concern with the use of ERAAs in postmenopausal women, and compounds in this class differ in their effects on the endometrium. Raloxifene, bazedoxifene, and ospemifene had no preclinical uterotrophic or negative histologic effects; these findings correlate with their endometrial safety profile in clinical trials. A semisystematic review of controlled studies in which postmenopausal women received raloxifene in combination with systemic estrogens found little evidence of endometrial safety concerns. Tamoxifen, in contrast, has been associated with a pronounced and lasting increase in endometrial thickness, reflecting the relative estrogenic activity identified in preclinical studies, and more importantly increased the risk of endometrial hyperplasia, carcinoma, and ovarian cysts. The combination of specific ERAAs and specific estrogens (whether systemic or vaginal) needs to be tested in large randomized controlled studies.
controlled trials, as effects on tissue may vary from agonist to antagonist, depending on the specific combination and the dose tested.

Limitations of this review include a paucity of preclinical and clinical urodynamic data on the effects of ERAAs on the urinary system. In addition, there are no available data on the effects of combined ospemifene and vaginal or systemic estrogen; however, as ospemifene monotherapy has beneficial effects on VVA, there is little reason to examine this combination. Although ospemifene is a metabolite of toremifene (an ERAA approved for the treatment of hormone-sensitive breast cancer), the use of ospemifene has not been evaluated in populations at high risk for breast or endometrial cancer, nor have potential effects on the bone, breast, and brain tissues been extensively studied; thus, no conclusions can be drawn about efficacy or safety in larger populations.

CONCLUSIONS

Ospemifene seems to have positive effects on the vagina and neutral effects on the urinary system, compared with the effects of raloxifene, bazedoxifene, and tamoxifen. The relative estrogenic agonist/antagonist activity of each ERAA in specific tissues seems to underlie many of the responses observed in preclinical models, several of which have translated into varying vaginal, endometrial, and urinary tract findings in clinical trials. Ospemifene can be differentiated from other ERAAs that have been approved or that are in late-stage development based on improvements in vaginal morphology, physical changes associated with VVA, and sexual function, and on its favorable endometrial and ovarian safety profile at 52 weeks. Ospemifene is an oral systemic ERAA, with unique effects on VVA, that does not need to be given with vaginal estrogen (unlike raloxifene) or systemic estrogen (unlike bazedoxifene). The unique clinical efficacy and safety profile of ospemifene supports its indication for treating moderate to severe dyspareunia associated with VVA in postmenopausal women. We need more data regarding its effects on other tissues (including the cardiovascular system, bone, breast, and central nervous system) and on vulnerable populations such as women at risk for breast or endometrial cancer.

REFERENCES

1. Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys 2010;503:118-128.
2. Raz R. Urinary tract infection in postmenopausal women. Korean J Urol 2011;52:801-808.
3. Bakos O, Smith P, Heimer G, Ullstein U. Transvaginal sonography of the internal genital organs in postmenopausal women on low-dose estrogen treatment. Ultrasound Obstet Gynecol 1994;4:326-329.
4. Sultana CJ, Walters MD. Estrogen and urinary incontinence in women. Maturitas 1994;20:129-138.
5. Sturdee DW, Pines A, International Menopause Society Writing Group, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:192-220.
6. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
7. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health 2009;1:105-111.
8. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-271.
9. Madak-Erodugan Z, Chan TH, Jiang Y, Liu ET, Katzenellenbogen JA, Katzenellenbogen BS. Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol 2013;9:676.
10. Leitman DC, Paruthiyil S, Vivar OI, et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol 2010;10:629-636.
11. Zheng H, Kangas L, Harkonen PL. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus. J Steroid Biochem Mol Biol 2004;88:143-156.
12. Wurz GT, Hellmann-Blumberg U, DeGregorio MW. Pharmacologic effects of ospemifene in thymus macaques: a pilot study. Basic Clin Pharmacol Toxicol 2008;102:552-558.
13. Unkila M, Kari S, Yatkin E, Lamminintiausta R. Vaginal effects of ospemifene in the ovarietomized rat preclinical model of menopause. J Steroid Biochem Mol Biol 2013;138:107-115.
14. Qu Q, Zheng H, Dahlund J, et al. Selective estrogenic effects of a novel triphenylethylenepropane, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovarietomized rats. Endocrinology 2000;141:809-820.
15. Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause 2012;19:96-103.
16. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77:271-279.
17. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylnbenzanthracene-induced mammary tumors in Senac mice. J Steroid Biochem Mol Biol 2005;97:230-240.
18. Michael H, Härkönen PL, Kangas L, Viinämäen HK, Hentunen TA. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007;151:384-395.
19. Qu Q, Härkönen PL, Viinämäen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999;73:500-507.
20. Sygár D, Muravitskaya N, Eriksson B, Eriksson H, Sahlin L. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 2003;1:40.
21. Fitts JM, Klein RM, Powers CA. Tamoxifen regulation of bone growth and endocrine function in the ovarietomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein–coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780). J Pharmacol Exp Ther 2011;338:264-254.
22. Feng CJ, Burgoon LD, Williams KJ, Jones AD, Forgas AL, Zacharewski TR. Effects of tamoxifen and ethynylestradiol cotreatment on uterine gene expression in immature, ovarietomized mice. J Mol Endocrinol 2010;45:161-173.
23. Al-Jamal JH, Dubin NH. The effect of raloxifene on the uterine weight response in immature mice exposed to 17β-estradiol, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)kethane, and methoxychlor. Am J Obstet Gynecol 2000;182:1099-1102.
24. Kim NN, Stankovic M, Armagan A, Cushman TT, Goldstein I, Traish AM. Effects of tamoxifen on vaginal blood flow and epithelial morphology in the rat. BMC Womens Health 2006;6:14.
25. Nunez NP, Jelovac MS, Maggiori M, et al. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Clin Cancer Res 2004;10:5375-5380.
26. Feng CJ, Burgoon LD, Williams KJ, Forgas AL, Zacharewski TR. Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovarietomized mice. BMC Genomics 2007;8:151.
27. Sikoski P, Register TC, Lees CJ, et al. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethynyl estradiol on the uterus, vagina and breast in ovarietomized cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 2007;196:75.e1-75.e7.

© 2014 The North American Menopause Society
70. Flamini MI, Sanchez AM, Goglia L, Tosi V, Genazzani AR, Simoncini T. Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells. Mol Hum Reprod 2009;15:675-685.

71. Glaeser M, Niederacher D, Djahansouzi S, et al. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery. Anticancer Res 2006;26:735-744.

72. Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25:45-71.

73. MacGregor JJ, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998;50:151-196.

74. Levy N, Tatomer D, Herber CB, et al. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 2008;22:287-303.

75. Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids 2015;78:1273-1280.

76. Constantine G, Graham S, Portman DJ, Rosen RC; Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. [published online ahead of print September 25, 2014]. Climacteric doi:10.3109/13697137.2014.945996.

77. Bachmann G, Bobula J, Mirkin S. Effects of bazoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132-140.

78. Duavee® (Conjugated Estrogens/Bazedoxifene). Full Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals; 2013.

79. Lobo RA, Pinkerton JV, Jass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.

80. Parsons A, Merritt D, Rosen A, et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-352.

81. Pinkerton JV, Shifren JL, La Vallee J, Rosen A, Rosemig M, Siddhant S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:45-52.

82. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (“Arimidex,” tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-284.

83. Wood CE, Kaplan JR, Fontenot MB, Williams JK, Cline JM. Endometrial profile of tamoxifen and low-dose estradiol combination therapy. Clin Cancer Res 2010;16:946-956.

84. Tsujioka S, Ban Y, Wise LD, et al. Collaborative work on evaluation of ovarian toxicity, 3: effects of 2- or 4-week repeated-dose toxicity and fertility studies with tamoxifen in female rats. J Toxicol Sci 2009;34 (suppl 1):SP43-SP51.

85. Long GG, Cohen JR, Gries CL, Young JK, Francis PC, Capen CC. Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator. Toxicol Pathol 2001;29:719-726.

86. Martino S, Dirsch D, Dowsett SA,Keetch CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-1457.

87. Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int 2007;13:27-34.

88. Cohen I, Perel E, Flex D, et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-282.

89. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706.

90. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-375.

91. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-1170.

92. Mofrad MH, Shandiz FH, Roodsare FV, Moghimian T. Evaluation of ovarian cysts in breast cancer cases on tamoxifen. Asian Pac J Cancer Prev 2010;11:161-164.

93. Kim HS, Jeon YT, Kim YB. The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients. J Gynecol Oncol 2008;19:256-260.

94. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-1115.

95. Sharma A, Gentry-Maharaj A, Burnell M, et al. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. BJOG 2012;119:207-219.

96. Breyer BN, Wang G, Lin G, et al. The effect of long-term hormonal treatment on voiding patterns during filling cystometry and on urethral histology in a postpartum, ovariectomized female rat. BJU Int 2010;106:1775-1781.

97. Tantiwongse K, Fandel TM, Wang G, et al. The potential of hormones and selective oestrogen receptor modulators in preventing voiding dysfunction in rats. BJU Int 2008;102:242-246.

98. dos Santos AR, Lopes-Costa PV, Borges CS, et al. Effects of raloxifene on the urothelium of adult castrated female rats. Climacteric 2008;11:483-488.

99. Acrar D, Cayan S, Aktas S, Tek M, Akbay E. The effect of tamoxifen on bladder functions and histology, and the role of estrogen receptor β in a rat chemical cystitis model. Neurourol Urodyn 2007;26:309-316.

100. Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 2005;8:214-220.

101. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013;8:135-155.

102. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521-527.

103. Warming L, Christoffersen BJ, Riis BJ, Delmas PD, Christiansen C. Adverse effects of a SERM (levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003;44:189-199.

104. Munster PN. Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs 2006;15:317-326.

105. Gennari L. Lasofoxifene, a new selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-1115.

106. Arevalo MA, Santos-Galindo M, Lagunas N, Azcoitia I, Garcia-Segura LM. Selective estrogen receptor modulators as brain therapeutic agents. J Mol Endocrinol 2011;46:R1-R9.

107. Carneiro AL, de Cassia de Maio Dardes R, Haidar MA. Estrogens plus raloxifene on endometrial safety and menopausal symptoms—semi systematic review. Menopause 2012;19:830-834.

Copyright © 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.